172 related articles for article (PubMed ID: 30728774)
1. Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs.
Zolotovskaia MA; Sorokin MI; Emelianova AA; Borisov NM; Kuzmin DV; Borger P; Garazha AV; Buzdin AA
Front Pharmacol; 2019; 10():1. PubMed ID: 30728774
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs.
Zolotovskaia M; Sorokin M; Garazha A; Borisov N; Buzdin A
Methods Mol Biol; 2020; 2063():207-234. PubMed ID: 31667773
[TBL] [Abstract][Full Text] [Related]
3. Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers.
Zolotovskaia MA; Sorokin MI; Roumiantsev SA; Borisov NM; Buzdin AA
Front Oncol; 2018; 8():658. PubMed ID: 30662873
[TBL] [Abstract][Full Text] [Related]
4. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
5. A systematic analysis of FDA-approved anticancer drugs.
Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
[TBL] [Abstract][Full Text] [Related]
6. Whole-Exome Sequencing Identifies Somatic Mutations Associated With Mortality in Metastatic Clear Cell Kidney Carcinoma.
Mendoza-Alvarez A; Guillen-Guio B; Baez-Ortega A; Hernandez-Perez C; Lakhwani-Lakhwani S; Maeso MD; Lorenzo-Salazar JM; Morales M; Flores C
Front Genet; 2019; 10():439. PubMed ID: 31156702
[TBL] [Abstract][Full Text] [Related]
7. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
8. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
[TBL] [Abstract][Full Text] [Related]
9. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.
Sousa FG; Matuo R; Tang SW; Rajapakse VN; Luna A; Sander C; Varma S; Simon PH; Doroshow JH; Reinhold WC; Pommier Y
DNA Repair (Amst); 2015 Apr; 28():107-15. PubMed ID: 25758781
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
[TBL] [Abstract][Full Text] [Related]
12. Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
Buckley AR; Ideker T; Carter H; Harismendy O; Schork NJ
Genome Med; 2018 Sep; 10(1):69. PubMed ID: 30217226
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Venkova L; Aliper A; Suntsova M; Kholodenko R; Shepelin D; Borisov N; Malakhova G; Vasilov R; Roumiantsev S; Zhavoronkov A; Buzdin A
Oncotarget; 2015 Sep; 6(29):27227-38. PubMed ID: 26317900
[TBL] [Abstract][Full Text] [Related]
14. An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types.
Park S; Kim SJ; Yu D; Peña-Llopis S; Gao J; Park JS; Chen B; Norris J; Wang X; Chen M; Kim M; Yong J; Wardak Z; Choe K; Story M; Starr T; Cheong JH; Hwang TH
Bioinformatics; 2016 Jun; 32(11):1643-51. PubMed ID: 26635139
[TBL] [Abstract][Full Text] [Related]
15. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
Ye H; Zhang X; Chen Y; Liu Q; Wei J
Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
[TBL] [Abstract][Full Text] [Related]
16. Discovery of mutated subnetworks associated with clinical data in cancer.
Vandin F; Clay P; Upfal E; Raphael BJ
Pac Symp Biocomput; 2012; ():55-66. PubMed ID: 22174262
[TBL] [Abstract][Full Text] [Related]
17. [Aiming for zero blindness].
Nakazawa T
Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
[TBL] [Abstract][Full Text] [Related]
18. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM; Heining C; Agaimy A; Huebschmann D; Bonekamp D; Hutter B; Ehrenberg KR; Fröhlich M; Schlesner M; Scholl C; Schlemmer HP; Wolf S; Mavratzas A; Jung CS; Gröschel S; von Kalle C; Eils R; Brors B; Penzel R; Kriegsmann M; Reuss DE; Schirmacher P; Stenzinger A; Federspil PA; Weichert W; Glimm H; Fröhling S
Ann Oncol; 2017 Jan; 28(1):142-148. PubMed ID: 27687311
[TBL] [Abstract][Full Text] [Related]
19. Rational design and identification of immuno-oncology drug combinations.
Iafolla MAJ; Selby H; Warner K; Ohashi PS; Haibe-Kains B; Siu LL
Eur J Cancer; 2018 May; 95():38-51. PubMed ID: 29631102
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel mutations in endometrial cancer patients by whole-exome sequencing.
Chang YS; Huang HD; Yeh KT; Chang JG
Int J Oncol; 2017 May; 50(5):1778-1784. PubMed ID: 28339086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
